AU2016291228B2 - Compositions and methods for treating lung diseases and lung injury - Google Patents

Compositions and methods for treating lung diseases and lung injury Download PDF

Info

Publication number
AU2016291228B2
AU2016291228B2 AU2016291228A AU2016291228A AU2016291228B2 AU 2016291228 B2 AU2016291228 B2 AU 2016291228B2 AU 2016291228 A AU2016291228 A AU 2016291228A AU 2016291228 A AU2016291228 A AU 2016291228A AU 2016291228 B2 AU2016291228 B2 AU 2016291228B2
Authority
AU
Australia
Prior art keywords
mol
composition
lipid
rnai
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016291228A
Other languages
English (en)
Other versions
AU2016291228A1 (en
Inventor
Kuan-Ju CHEN
Keith DIPETRILLO
Franziska LEIFER
Vladimir Malinin
Walter Perkins
Jimin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insmed Inc
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of AU2016291228A1 publication Critical patent/AU2016291228A1/en
Application granted granted Critical
Publication of AU2016291228B2 publication Critical patent/AU2016291228B2/en
Priority to AU2020203367A priority Critical patent/AU2020203367A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2016291228A 2015-07-09 2016-07-11 Compositions and methods for treating lung diseases and lung injury Active AU2016291228B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020203367A AU2020203367A1 (en) 2015-07-09 2020-05-22 Compositions and methods for treating lung diseases and lung injury

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190583P 2015-07-09 2015-07-09
US62/190,583 2015-07-09
PCT/US2016/041776 WO2017008076A1 (en) 2015-07-09 2016-07-11 Compositions and methods for treating lung diseases and lung injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203367A Division AU2020203367A1 (en) 2015-07-09 2020-05-22 Compositions and methods for treating lung diseases and lung injury

Publications (2)

Publication Number Publication Date
AU2016291228A1 AU2016291228A1 (en) 2017-12-07
AU2016291228B2 true AU2016291228B2 (en) 2020-04-09

Family

ID=57686097

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016291228A Active AU2016291228B2 (en) 2015-07-09 2016-07-11 Compositions and methods for treating lung diseases and lung injury
AU2020203367A Abandoned AU2020203367A1 (en) 2015-07-09 2020-05-22 Compositions and methods for treating lung diseases and lung injury

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020203367A Abandoned AU2020203367A1 (en) 2015-07-09 2020-05-22 Compositions and methods for treating lung diseases and lung injury

Country Status (7)

Country Link
US (1) US20180200186A1 (https=)
EP (1) EP3319976B1 (https=)
JP (1) JP6884714B2 (https=)
AU (2) AU2016291228B2 (https=)
CA (1) CA2989884A1 (https=)
ES (1) ES2898340T3 (https=)
WO (1) WO2017008076A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029994T2 (en) 2005-12-08 2017-04-28 Insmed Inc Lipid-based compositions of antiinfectives for treating pulmonary infections
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
RU2018135921A (ru) 2012-11-29 2019-02-05 Инсмед Инкорпорейтед Стабилизированные составы ванкомицина
LT3060041T (lt) 2013-10-25 2021-03-25 Insmed Incorporated Prostaciklino junginiai
SMT202000516T1 (it) 2014-05-15 2020-11-10 Insmed Inc Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
WO2019213398A1 (en) 2018-05-02 2019-11-07 Insmed Incorporated Methods for the manufacture of liposomal drug formulations
US11517548B2 (en) * 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease
CN112996519B (zh) * 2018-09-04 2025-02-28 德克萨斯大学系统董事会 用于核酸的器官特异性递送的组合物和方法
CN113166783B (zh) 2018-10-09 2024-10-11 不列颠哥伦比亚大学 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
CN109432047B (zh) * 2018-10-29 2021-07-20 中国药科大学 一种逆转肺纤维化纳米制剂及其制备方法
JP7455144B2 (ja) 2019-04-29 2024-03-25 インスメッド インコーポレイテッド トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
JP7674354B2 (ja) * 2019-12-05 2025-05-09 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 肝線維症および線維症に関連する他の疾患に対するエキソソームベースの療法
GB2632565B (en) 2020-04-09 2025-06-04 Verve Therapeutics Inc Base editing of PCSK9 and methods of using same for treatment of disease
AU2021305214A1 (en) * 2020-07-10 2023-02-23 Genevant Sciences Gmbh Lipid nanoparticles for delivering therapeutics to lungs
JP2023549011A (ja) 2020-09-15 2023-11-22 ヴァーヴ・セラピューティクス，インコーポレーテッド 遺伝子編集のための脂質製剤
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
JP2024511463A (ja) 2021-03-22 2024-03-13 リコード セラピューティクス，インク． 細胞への標的送達のための組成物および方法
CN113058042B (zh) * 2021-04-01 2023-06-30 易慧生物技术(上海)有限公司 一种可鼻喷的稳定递载rna分子的脂质纳米颗粒制备方法
JP2024520834A (ja) * 2021-06-09 2024-05-24 レコード・セラピューティクス・インコーポレイテッド ポリヌクレオチド組成物、関連する製剤及びその使用方法
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
WO2023019192A1 (en) * 2021-08-11 2023-02-16 Board Of Regents, The University Of Texas System Dry liposome formulations and related methods thereof
US20240382425A1 (en) * 2021-08-14 2024-11-21 Bs Biotechna Spolka Z Ograniczona Odpowiedzialnoscia RNA binding and stabilising cationic liposome, its application and method of loading the liposome with emetine
EP4226949A1 (en) * 2022-02-14 2023-08-16 Pantherna Therapeutics GmbH Preparation for use in a method for the treatment and/or prevention of a disease
WO2024242216A1 (ko) * 2023-05-23 2024-11-28 주식회사 케이더블유바이오 대식세포 표적화 리포좀 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2199298A1 (en) * 2004-11-17 2010-06-23 Protiva Biotherapeutics Inc. Sirna silencing of Apolipoprotein B
WO2011108955A1 (en) * 2010-03-03 2011-09-09 Universidade De Coimbra Multi -targeting system comprising a nanocarrier, nucleic acid(s) and non-nucleic acid based drug(s)
US20140308304A1 (en) * 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US4861580A (en) * 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1666606A4 (en) * 2003-08-20 2006-11-29 Locomogene Inc METHODS FOR IDENTIFYING REGULATORY EFFECTS ON THE ACTIVITY OF SYNOVIOLIN
CN104119242B (zh) * 2008-10-09 2017-07-07 泰米拉制药公司 改善的氨基脂质和递送核酸的方法
CA2801066C (en) * 2010-06-02 2021-02-09 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
CA2925687A1 (en) * 2012-09-27 2014-04-03 The University Of North Carolina At Chapel Hill Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2199298A1 (en) * 2004-11-17 2010-06-23 Protiva Biotherapeutics Inc. Sirna silencing of Apolipoprotein B
WO2011108955A1 (en) * 2010-03-03 2011-09-09 Universidade De Coimbra Multi -targeting system comprising a nanocarrier, nucleic acid(s) and non-nucleic acid based drug(s)
US20140308304A1 (en) * 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents

Also Published As

Publication number Publication date
CA2989884A1 (en) 2017-01-12
AU2020203367A1 (en) 2020-06-11
US20180200186A1 (en) 2018-07-19
JP2018519818A (ja) 2018-07-26
ES2898340T3 (es) 2022-03-07
WO2017008076A1 (en) 2017-01-12
EP3319976A4 (en) 2019-03-20
AU2016291228A1 (en) 2017-12-07
EP3319976A1 (en) 2018-05-16
JP6884714B2 (ja) 2021-06-09
EP3319976B1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
AU2016291228B2 (en) Compositions and methods for treating lung diseases and lung injury
JP6990176B2 (ja) メッセンジャーリボ核酸薬物の治療投与のための方法
JP6023126B2 (ja) 標的遺伝子の発現を抑制する組成物
US20070293449A1 (en) Compositions and methods for delivery of double-stranded rna
US20080076701A1 (en) Dicer substrate rna peptide conjugates and methods for rna therapeutics
JP2024541993A (ja) Ｒｎａコンストラクト及びその使用
CN114096274A (zh) 免疫治疗构建体以及其使用方法
CN101346393A (zh) 修饰的siRNA分子及其应用
CN118319880B (zh) 靶向肺部高效递送核酸的脂质纳米颗粒、吸入式制剂及应用
EP4041400B1 (en) Messenger rnas encoding sting and il-12 and use in the treatment of cancer
CN118766874B (zh) 一种吸入式制剂、迭代优化流程及其应用
KR102931885B1 (ko) 대식세포 유래 소포로 코팅된 지질 나노입자 및 이의 제조 방법
JP2021518345A (ja) 喘息またはアレルギー性疾患を処置するための方法
CN120092014A (zh) Rna构建体和其用途
WO2024026257A2 (en) Engineered polynucleotides for cell selective expression
JP2024534066A (ja) 脂質ナノ粒子製剤
You et al. p65 siRNA-loaded buformin/DNA nanoprisms alleviate acute lung injury through inhibiting NLRP3-mediated pyroptosis
WO2023240225A1 (en) Constitutively active polymeric sting mimics for antitumor immunity
JP2023039115A (ja) 物質送達キャリア及び組成物
JP5872898B2 (ja) 標的遺伝子の発現を抑制する組成物
WO2012098692A1 (ja) 標的遺伝子の発現を抑制する組成物
WO2025149492A1 (en) Rna encoding an immune inhibitory il-1 family member

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)